CELCUITY LLC
NASDAQ: CELC (Celcuity Inc.)
Kemas kini terakhir: 2 jam lalu114.22
1.59 (1.41%)
| Penutupan Terdahulu | 112.63 |
| Buka | 112.54 |
| Jumlah Dagangan | 851,343 |
| Purata Dagangan (3B) | 729,443 |
| Modal Pasaran | 5,521,015,296 |
| Harga / Buku (P/B) | 54.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2026 |
| EPS Cair (TTM) | -3.05 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.89% |
| Nisbah Semasa (MRQ) | 6.61 |
| Aliran Tunai Operasi (OCF TTM) | -102.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.83 M |
| Pulangan Atas Aset (ROA TTM) | -39.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Celcuity Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.21% |
| % Dimiliki oleh Institusi | 81.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Dec 2025 | 7,915,792 |
| Nea Management Company, Llc | 31 Dec 2025 | 3,535,561 |
| Perceptive Advisors Llc | 31 Dec 2025 | 3,160,200 |
| Avoro Capital Advisors Llc | 31 Dec 2025 | 3,111,111 |
| Soleus Capital Management, L.P. | 31 Dec 2025 | 1,808,258 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 1,714,000 |
| Tang Capital Management Llc | 31 Dec 2025 | 1,050,000 |
| Holocene Advisors, Lp | 31 Dec 2025 | 695,340 |
| Julat 52 Minggu | ||
| Median | 122.00 (6.81%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 10 Mar 2026 | 122.00 (6.81%) | Beli | 117.10 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BULLER RICHARD E | - | 114.14 | -3,000 | -342,420 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -342,420 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 114.14 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BULLER RICHARD E | Pengarah | 31 Mar 2026 | Jual automatik (-) | 3,000 | 114.14 | 342,420 |
| BULLER RICHARD E | Pengarah | 31 Mar 2026 | Pelaksanaan pilihan | 3,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 20 Jan 2026 | Pengumuman | Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |